Supernus Pharmaceuticals, Inc. (SUPN) Stock Overview
Explore Supernus Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Supernus Pharmaceuticals, Inc. (SUPN)
Key Financials
Key Financials
Market Cap
2.6B
P/E Ratio
-22.93
EPS (TTM)
$3.06
ROE
-0.10%
SUPN Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Supernus Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of SUPN on the NASDAQ shows an RSI of 40.02, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $57.29 for the NASDAQ listing.
Key metrics behind Supernus Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -22.93 and a market capitalization of 2.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of SUPN on the NASDAQ.